A Decade to Diagnosis
Endometriosis affects approximately 10% of women of reproductive age worldwide — a figure that translates to roughly 190 million people globally. It is associated with significant dysmenorrhoea, chronic pelvic pain, dyspareunia, and in many cases, subfertility. It is also associated with a diagnostic delay that, by any reasonable clinical standard, is unacceptable. Multiple population studies across the UK, USA, Australia, and Europe have placed the average time from symptom onset to confirmed endometriosis diagnosis at between 7 and 10 years.
In some healthcare systems and clinical contexts, the delay is longer still. In a condition where disease progression can cause lasting anatomical damage — adhesion formation, ovarian endometrioma development, tubal involvement, altered peritoneal environment — this is not a passive wait. It is years of progressive, often
untreated pathology accumulating consequences that affect both quality of life and future reproductive capacity.
Why the Delay Persists
The causes of endometriosis diagnostic delay are multiple, intersecting, and stubborn. They include the long-standing cultural normalisation of menstrual pain — a pattern that leads both patients and clinicians to dismiss symptoms that should be triggering investigation. They include the absence of a reliable non-invasive diagnostic
standard: ultrasound, in experienced hands, can identify certain endometriosis presentations, but its sensitivity varies widely. Histological confirmation has traditionally required laparoscopy, creating a barrier to early investigation that many healthcare systems have not adequately addressed. There is also a well-documented gender dimension to this delay. Research across multiple medical specialties has demonstrated that women’s pain is systematically underestimated and undertreated compared to equivalent pain in men. In the context
of endometriosis, this manifests as patients who report significant, recurring, cyclical pain and are told — repeatedly, by multiple clinicians — that what they are experiencing is simply a normal part of being a woman. The clinical and ethical cost of that dismissal is high.
What Progressive Disease Costs Reproductively
Approximately 30–50% of women with endometriosis will experience some degree of subfertility. The mechanisms are multiple: endometriomas can reduce ovarian reserve and affect egg quality; adhesions can distort tubal architecture and impair egg pickup; the inflammatory peritoneal environment may affect fertilisation and implantation; and the increasingly recognised relationship between endometriosis and adenomyosis carries its own implications for uterine receptivity. Crucially, much of this damage is progressive. Stage I or Stage II disease identified and managed early carries a substantially better reproductive prognosis than the same condition diagnosed after years of unmanaged progression. A patient whose endometriosis is finally confirmed at Stage III or IV — after a decade of dismissed pain — is presenting with a fertility landscape that is fundamentally different from what it might have been with earlier intervention.
The Fertility Consultation as a Diagnostic Opportunity
For fertility specialists and reproductive endocrinologists, there is a specific responsibility here. Many women with endometriosis receive their diagnosis — or their first serious investigation — during a fertility consultation, not before it. A systematic approach to endometriosis enquiry in all patients presenting with subfertility — including detailed menstrual history, pain history, and appropriate ultrasound evaluation by a practitioner experienced in endometriosis imaging — is a clinical habit with meaningful downstream implications. The patient who has spent a decade managing ‘difficult periods’ may be in a fertility clinic for the first time. It may also be the first time anyone has asked the right questions.
The Conversation That Changes Outcomes
Earlier diagnosis requires coordinated effort: better endometriosis education at the primary care and gynaecology level, improved non-invasive diagnostic pathways, updated clinical guidelines that lower the threshold for investigation, and a collective commitment to take cyclical pelvic pain seriously from the moment it is reported.
For those in reproductive medicine: how has your clinical approach to endometriosis investigation evolved? And where, in your experience, does the most significant diagnostic gap still lie?
